GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gelesis Holdings Inc (OTCPK:GLSHQ) » Definitions » ROE %

Gelesis Holdings (Gelesis Holdings) ROE % : 0.00% (As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Gelesis Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Gelesis Holdings's annualized net income for the quarter that ended in Jun. 2023 was $-30.72 Mil. Gelesis Holdings's average Total Stockholders Equity over the quarter that ended in Jun. 2023 was $-29.11 Mil. Therefore, Gelesis Holdings's annualized ROE % for the quarter that ended in Jun. 2023 was N/A%.

The historical rank and industry rank for Gelesis Holdings's ROE % or its related term are showing as below:

GLSHQ's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -43.41
* Ranked among companies with meaningful ROE % only.

Gelesis Holdings ROE % Historical Data

The historical data trend for Gelesis Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gelesis Holdings ROE % Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
ROE %
- -

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only -665.86 -7,568.62 - - -

Competitive Comparison of Gelesis Holdings's ROE %

For the Biotechnology subindustry, Gelesis Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gelesis Holdings's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gelesis Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Gelesis Holdings's ROE % falls into.



Gelesis Holdings ROE % Calculation

Gelesis Holdings's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-57.128/( (-329.836+-25.056)/ 2 )
=-57.128/-177.446
=N/A %

Gelesis Holdings's annualized ROE % for the quarter that ended in Jun. 2023 is calculated as

ROE %=Net Income (Q: Jun. 2023 )/( (Total Stockholders Equity (Q: Mar. 2023 )+Total Stockholders Equity (Q: Jun. 2023 ))/ count )
=-30.724/( (-26.689+-31.53)/ 2 )
=-30.724/-29.1095
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Gelesis Holdings  (OTCPK:GLSHQ) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=-30.724/-29.1095
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-30.724 / 4.428)*(4.428 / 97.3275)*(97.3275 / -29.1095)
=Net Margin %*Asset Turnover*Equity Multiplier
=-693.86 %*0.0455*N/A
=ROA %*Equity Multiplier
=-31.57 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=-30.724/-29.1095
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-30.724 / -30.724) * (-30.724 / -39.984) * (-39.984 / 4.428) * (4.428 / 97.3275) * (97.3275 / -29.1095)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.7684 * -902.98 % * 0.0455 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Gelesis Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Gelesis Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gelesis Holdings (Gelesis Holdings) Business Description

Traded in Other Exchanges
N/A
Address
501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Executives
Raju S Kucherlapati director 77 LOUIS PASTEUR AVENUE, BOSTON MA 02115
Bomsmaster Llc 10 percent owner 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510
Paul R. Fonteyne director C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Hpso Spv Ltd 10 percent owner SARNIA HOUSE, LE TRUCHOT, ST PETER PORT Y7 GY1 4NA
Alessandro Sannino officer: Lead Project Scientist C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Dominic Perks director GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON NY 02116
David A. Pass officer: Chief Op. & Comm. Officer GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON MA 02116
Elaine Chiquette officer: Chief Scientific Officer C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Jane Wildman director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Harry L. Leider officer: Chief Medical Officer C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Clayton Christopher director 2407 S. CONGRESS AVE, SUITE E103, AUSTIN TX 78704
Health Plc Puretech 10 percent owner 6 TIDE STREET, SUITE 400, BOSTON MA 02210
Ssd2, Llc 10 percent owner 142 TEMPLE STREET, SUITE 206, NEW HAVEN CT 06511
Yishai Zohar director, officer: President & CEO C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Elon Boms 10 percent owner C/O THIMBLE POINT ACQUISITION CORP., 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510

Gelesis Holdings (Gelesis Holdings) Headlines

From GuruFocus

Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022

By Business Wire Business Wire 05-09-2022

Gelesis to Participate in Upcoming Investor Conferences

By Business Wire Business Wire 05-18-2022